In response to reports claiming companies are not providing medication on credit as a result of the unfavourable for our country developments in the economy, the Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) assures consumers that the private as well as the public sector have sufficient pharmaceutical reserves and there have been no shortages on the market.
KEFEA is in contact with those immediately involved in the matter and is taking measures to ensure Cypriot patients’ access to medication continues unhindered. When the need arises and under any circumstance, the public will continue to have access to essential medicines provided by the Association’s members.
KEFEA stresses that there is no excuse for creating a climate of panic and it reassures the public that pharmaceutical companies are dealing with the consequences of the crisis our country is going through responsibly and consistently.
Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) www.kefea.org.cy
The Cyprus Association of Research & Development Pharmaceutical Companies (KEFEA) was founded in 2006 as the representative body of multinational pharmaceutical companies in Cyprus. Its members are GSK, Lilly, MSD, Novartis, Pfizer, Sanofi and Amgen Hellas altogether employing more than 300 people in Cyprus. It is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). KEFEA’s mission is to provide Cypriots with innovative medicines. Its objectives are to ensure uninterrupted access to medicines at reasonable prices in the Cyprus market, given the acknowledgement of budgetary constraints, provide scientific educational information on diseases and treatments to healthcare providers, ensure that European objectives regarding high healthcare standards are implemented in the Cyprus market, and comply with a common code of ethical practice